Drug Trial Radar · NCT05996003
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Feb 22, 2024
Primary completion
Feb 26, 2027
Study completion Feb 26, 2027
Sponsor
- Lead sponsor
- NS Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nippon Shinyaku Co., Ltd.
- First posted
- Aug 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 4 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly. The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.
Conditions
- Duchenne Muscular Dystrophy
- Exon 44
- DMD
Interventions
NS-089/NCNP-02Drug
Cohort 1: Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1 Cohort 2: Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event and Adverse Drug ReactionTime frame: through study completion, up to follow-up phone call for Part 2
- Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Maximum plasma concentration (Cmax) of NS-089/NCNP-02
- Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Time of the maximum plasma concentration (Tmax) of NS-089/NCNP-02
- Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Terminal half-life (T1/2) of NS-089/NCNP-02
- Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Area under the concentration-time curve from time 0 to the last time point (AUC0-t) of NS-089/NCNP-02
- Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Area under the concentration-time curve from time 0 to infinity (AUC0-∞) of NS-089/NCNP-02
- Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Total body clearance (CLtot) of NS-089/NCNP-02
- Plasma pharmacokinetic (PK) parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] The volume in the terminal state (Vz) of NS-089/NCNP-02
- Urine pharmacokinetic parametersTime frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Urinary excretion of NS-089/NCNP-02
- Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot).Time frame: Baseline, Week25
Locations
29 sites in 7 countries. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
Rare Disease Research
Atlanta, Georgia
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Kansas Medical Center (KUMC)
Kansas City, Kansas
Boston Children's Hospital
Boston, Massachusetts
Columbia University Pediatric Neuromuscular Center
New York, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
The Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
UT Southwestern/Children's Health
Dallas, Texas
Virginia Commonwealth University Health System
Richmond, Virginia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
Perth Children's Hospital
Nedlands, Western Australia, Australia
Alberta Children's Hospital
Calgary, Alberta, Canada
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
London Health Sciences Centre
London, Ontario, Canada
Fukui Prefectural Hospital
Fukui-shi, Fukui, Japan
National Hospital Organization Nagara Medical Center
Nagara, Gifu-shi, Gifu, Japan
NHO Osaka Toneyama Medical Center
Toyonaka, Osaka, Japan
Shiga General Hospital
Moriyama-shi, Shiga, Japan
National Center of Neurology and Psychiatry
Kodaira, Tokyo, Japan
Starship Children's Hospital
Auckland, New Zealand
Seoul National University Hospital
Seoul, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam, South Korea
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
Istanbul University- Istanbul Faculty of Medicine
Istanbul, Turkey (Türkiye)
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey (Türkiye)
S.B.U. Dr. Behcet uz Pediatric Diseases and Surgery Training and Research Hospital
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.